July 9, 2015

Financial Technology Partners

FT Partners Research - IPO Profile



completes its IPO raising \$209 million

NYSE: EVH

Courtesy of:



The Only Investment Bank Focused Exclusively on Financial Technology

www.ftpartners.com



Steve McLaughlin

Managing Partner

Tel: 415.992.8880

steve.mclaughlin@ftpartners.com

Financial Technology Partners 555 Mission St., 23rd Floor San Francisco, CA 94105

Tel: 415.512.8700



Transaction Overview

Key IPO Statistics

Headquarters: Arlington, VA

Founded: 2011

Employees: 836 (1)

Initial Filing Date: May 5, 2015

Trading Date: June 5, 2015

Ticker: NYSE: EVH

Initial Filing Range: \$14.00 - \$16.00

Offer Price: \$17.00

First Day Open: \$18.00

First Day Close: \$18.86

Current Price (2): \$18.97

Shares Offered (3): 13,225,000

Net Proceeds: \$209,000,000

Description: Evolent Health, Inc. provides a technology

enabled platform (Identifi®) and services that enable health providers to switch from fee-forservice reimbursement to value-based payment models that actually reward high-quality and cost

effective care

UNITED STATES SECURITIES AND EXCHANGE COMISSION

Form S-1

Evolent Health, Inc.



NYSE: EVH

Frank Williams
Chief Executive Officer
800 N. Glebe Road, Suite 500
Arlington, VA 22203

Joint Bookrunners





Co-Managers











Founders

The **Advisory**

Board Company

Part Owners


Evolent Health Completes its IPO

Company Overview

Company Overview

Evolent Health provides an end-to-end technology-enabled services platform helping healthcare providers transition to value based payment models

<u>Step 1</u> Blueprint → <u>Step 2</u> Value-Based Operations & Identifi ®



- UPMC operates the nation's largest provider-owned health plan behind Kaiser Permanente
- The Advisory Board provides best practice research and technology solutions to over 3,900 hospitals and providers
- Focused on large long-term customer contracts with health care providers and health systems
 - To date, Evolent Health has secured ten long-term contracts worth \$700 mm in future total contract value
 - Expects to continue to grow as the Companies' partners increase membership in existing value-based programs, through expanding product offering and acquiring new partners
- Every long-term partnership begins with a system transformation process called "Blueprint"
 - Evolent Health works with the healthcare provider's Board of Directors and senior management
 - A significant portion of providers that go through the Blueprint process continue to partner with the Company for its proprietary processes and services known as Value-Based Operations
- Value-Based models include Direct to Employer, Payer Contracts & Provider Owned Health Plans





Population Health Performance



Delivery Network Alignment

Clinical Programs

Patient Engagement

Specialized Care Team

Quality and Risk Coding

High Performance Network

Value Compensation Models

Integrated Specialty Partnerships



Financial and Administrative Management





Identifi® Technology Solution

Data & Integration
Services

Clinical & Business
Content

EMR Optimization

Applications

FINANCIAL
TECHNOLOGY
PARTNERS

🏏 in



Industry Overview

Market Opportunity

In 2014 U.S. healthcare spending exceeded

\$3 trillion

Evolent Health estimates

\$1 trillion

of that spending was a waste

The shift to value-based care can address this \$1 trillion opportunity

Evolent Health's estimate of its total market opportunity is

\$10 billion+

The opportunity size is estimated to grow to


> \$46 billion+ - By 2020

Health insurance expenditures increasing from \$2.1 trillion in 2013 → \$3.2 trillion by 2020

Total percentage of payments providers receive under valuebased care models is growing from 10% to 50% Providers are increasingly switching to valuebased payment models


10% of healthcare payments

are through value-based care programs including:



The number of programs using value-based care is estimated to grow to **50%** by 2020

Accountable Care



2010 2014

FINANCIAL TECHNOLOGY **PARTNERS**



Competitive Strengths

Evolent is wellpositioned to benefit from the transformation occurring in healthcare delivery Early Innovator with Proven Leadership

- Evolent is an innovator in the delivery of a comprehensive value-based care solution for providers
- The senior leadership team has an average of 15 years experience in the healthcare industry and a track record of delivering measurable clinical, financial and operational improvements

Comprehensive Technology Platform Proprietary platform allows the company to deliver a connected delivery ecosystem, implement replicable clinical processes, scale Value-Based Operations and capitalize on multiple types of value-based payment relationships

Provider-Centric Brand Identity

- Provider-centric brand identity and origins differentiate the company from competitors
- Solutions resonate with potential partners seeking solutions from providers, rather than payers or non-healthcare businesses

Partnership-Driven Business Model

- Evolent's business model is predicated on long-term strategic partnerships with leading providers that are attempting to evolve their care delivery and compensation
- This model enables cultural alignment, integration into the provider work flow, longterm relationships and a cycle of clinical and cost improvement with shared financial benefit

Channel Development

- Blueprint creates a connection between Evolent and the provider's senior leadership; as a result, revenues are derived from providers who proceed to partner and transition to value-based contracting
- The combined connections of UPMC and The Advisory board, whose reach extends to thousands of providers, have fostered the development of a significant channel into leading health systems for Evolent

FINANCIAL
TECHNOLOGY
PARTNERS

🏏 in



Growth Opportunities

Potential additions may Growth in government programs include, specialty PBM, will create an opportunity for Capitalize on Expand platform health savings accounts health systems to capture a growth in select offerings to meet administration and greater portion of the \$2 trillion in governmentevolving market consumer engagement / annual health insurance driven programs needs digital outreach expenditures Currently only capturing Well positioned to meet 10% of total premium evolent (evolving provider demand dollars through Capture additional Selectively pursue by expanding the breadth administrative expenses; value through strategic of products, both Have began pursuing delivering clinical acquisitions organically and through business models to capture **Growth Opportunities** results acquisitions the medical dollar Multiple In addition to growth within Early stages of a Existing partners represent avenues with existing partner base, rapidly growing a small fraction of health opportunities exist with providers existing, addressable systems that could benefit embedded utilizing Blueprint to convert market from Evolent's solutions



short-term contracts to long-term

operating partnerships

y in

partner base



Management Team

Frank Williams CEO, Co-Founder & Director

Mr. Williams also serves as Vice Chairman of The Advisory Board Committee, a global research, technology & consulting firm serving over 4,100 health care and higher education organizations



Steve

Wigginton

Mr. Wigginton is responsible for strategy, marketing and health system partnership development for Evolent Health

- During his tenure as both its Chairman and CEO, The Advisory Board completed an IPO and grew to \$450 mm+ in annual revenues with over 2,500 employees and \$2.0 bn+ in market capitalization

 Previously served at founding CEO of Medley Health and president of Health Integrated



- Mr. Blackley oversees company strategy, product design, sales, marketing, and business development
- Prior to Evolent, Mr. Blackley served as the **Executive Director of Corporate Development** and Strategic Planning at The Advisory **Board Committee**





- Mr. Pomeroy leads Evolent's information technology group
- Previous positions include CMO or Access Mediguip, VP of Strategy at Wellpoint and **CTO of Lumenos**



 Previously, Mr. Peterson served as the Vice **President of Managed Care and Payer** Relationships for HealthSouth Corporation in the Southeast

Berk Smith President. Strategic Alliance



Mr. Smith leads efforts to open new markets and structure Evolent Health's anchor partner relationships



❖ A founding member of Perot Systems Healthcare, acquired by Dell in 2011, Mr. Smith played a key role in building a \$3 bn global leader in healthcare services





- Mr. McGrane possesses a strong background in finance, with over twenty-five years of experience in banking, private equity, and operations
- Prior to joining Evolent, Mr. McGrane worked at MidOcean Partners and served as interim CEO of portfolio company Sbarro, where he led a financial and operational restructuring

Seth Frazier Chief Transformation Officer



- Mr. Frazier leads Evolent's transformation practice, contributing to the clinical innovation strategy
- * Most recently. Mr. Frazier served as the Chief Transformation Officer for the Geisinger Health System prior to joining **Evolent**





Board of Directors

Board of Directors										
Name	Title	Background								
David Farner UPMC CHANGING MEDICINE	Director / Executive Vice President, Chief Strategic and Transformation Officer, UPMC	 Executive vice president and chief of staff in the Office of the President at UPMC Works on UPMC strategic opportunities and initiatives, playing an active role in the executive direction of UPMC 								
Matt Hobart TPG	Director / Partner, TPG	 Partner with TPG, global private investment firm with \$55.3 bn of assets under management Previous board service includes the Vincraft Group, Schiff Nutrition International, Wil Research and Agraquest 								
Diane Holder UPMC Insurance Services Division	Director / President, UPMC Insurance Service Division; President and Chief Executive	 President of the University of Pittsburgh Medical Center, the UPMC Insurance Services Division and the UPMC Health Plan UPMC provides health coverage and benefit management for over one million men, women and children in Pennsylvania 								
Michael Kirshbaum The Advisory Board Company	Director / Chief Financial Officer, The Advisory Board Committee	 Joined The Advisory Board Company in 1998 and became the Chief Financial Officer in February 2006 and treasurer in March 2007 								
Robert Musslewhite The Advisory Board Company	Director / Chief Executive Officer and Chairman, The Advisory Board Committee	 Joined The Advisory Board in 2003 and became Chief Executive Officer in 2008 Prior to joining The Advisory Board, Mr. Musslewhite was an associate principal at McKinsey & Co Named a 2013 "Tech Titan" by Washingtonian Magazine 								
Norman Payson, MD evolent HEALTH	Director	 Co-founder and CEO of 3 million member health plan (Healthsource, 1985-1997) Chairman of the nation's largest occupational health care company (Concentra, 2005-2008) 								







Risks Relating to Business and Industry

- The market for healthcare in the U.S. is in the early stages of structural change and is rapidly evolving
 - Increasing difficulty to forecast annual performance
 - Reduces ability to accurately evaluate long term outlook and demand for products and services
- Consolidation in the healthcare industry
 - As consolidation accelerates partners may experience sizable growth and determine that it no longer need to rely on the Company and may reduce its demands
 - May result in partners acquisition or future development in competing products and services
 - Significant portion of revenues derived from largest partners
 - Five largest partners comprised approximately 78% in aggregate of revenue for the three months ended March 31, 2015
 - Because of this, Evolent Health depends on the creditworthiness of these partners
 - Requires consistent innovation and advanced in industry standards, technology, and partners' needs
- Success of partners are difficult to predict and are subject to external factors
 - Five largest partners comprised approximately 78% in aggregate of revenue for the three months ended March 31, 2015
 - Because of this, Evolent Health depends on the creditworthiness of these partners
 - Requires consistent innovation and advanced industry standards, technology, and partners' needs
- Incur significant upfront costs
 - Inability to develop or grow partner relationships over time will result in an unlikely recover of costs and unsolicited operating results

- Healthcare regulatory and political framework
 - Healthcare laws and regulations are evolving and may change significantly in the future, which may adversely affect the Company's financial condition and results of operation
 - If the Company were to become subject to litigation or liabilities under certain laws, its business could be adversely affected
- Trademarks and trade names are not adequately protected
 - May result in not being able to build name recognition in markets of industry
 - Inability to compete effectively and commercialize technologies or products in certain relevant countries
 - Loss of intellectual property rights to certain licensed technologies
 - Evolent Health relies on licenses to use various proprietary technologies that are material to its day-to-day business
 - Depends upon licenses from third parties for some of the technology and data used in the Company's applications and technology platforms
- Data loss or corruption due to failures or errors in the system or service
 - May adversely affect reputation and relationships with existing partners, which could have a negative impact on business, financial condition and results of operations
 - Evolent Health collects and manages large amounts of data creating the possibility of hardware failures or errors in the system that could result in data loss or corruption or contain inaccuracies within the data that partners regard as significant
- Intense competition
 - Limit ability to maintain or expand market share within industry
 - Competitors are constantly developing products and services that may become more efficient or appealing to existing and potential partners
 - If two are more competitors were to merge or partner, the change in the competitive landscape could also adversely affect the Company's ability to compete


FINANCIAL
TECHNOLOGY
PARTNERS


🏏 in



Financial Overview

Majority of Evolent Health's revenues come from several multi-year contracts - Evolent Health's business model benefits from scale as the Company leverages its platform and grows its partnerships












Financial Overview







PARTNERS



Selected Public Company Comparables

	<u>-</u>			Market	Enterprise				Multiples							Growth Rates			Margins		
	Price	% MTD	% LTM	Value	Value	Price / Earn		arnings	EV / EBITDA			EV / Revenue			Revenue		EPS	EBITDA		P/E/G	
Company Name	07/06/15	Change	High	(\$ mm)	(\$ mm)	LTM	CY15E	CY16E	LTM	CY15E	CY16E	LTM	CY15E	CY16E	CY15E	CY16E	LT	CY15E	CY16E	CY15E	
Healthcare Consulting																					
Towers Watson	\$ 130.52	3 %	92 %	\$ 9,087	\$ 8,547	25.4 x	21.3 x	18.9 x	12.0 x	11.2 x	10.4 x	2.4 x	2.3 x	2.2 x	2 %	8 %	13 %	21 %	21 %	1.6 x	
Advisory Board	54.38	0	96	2,333	2,246	nm	40.1	31.4	45.0	12.9	11.0	3.9	2.9	2.5	37	16	16	22	22	2.5	
FTI	41.93	(1)	96	1,710	2,196	22.0	20.0	16.2	10.3	9.5	8.2	1.2	1.2	1.1	3	7	14	13	14	1.4	
Huron Consulting	70.88	(0)	90	1,494	1,639	31.2	18.6	15.8	12.8	9.2	8.1	2.1	1.8	1.7	8	9	14	20	21	1.4	
Navigant	14.75	(0)	82	713	890	12.8	15.1	13.5	7.3	7.4	6.9	1.1	1.1	1.0	9	5	14	14	15	1.1	
CTG	8.30	6	49	157	123	14.0	21.6	17.3	7.2	11.2	7.9	0.3	0.3	0.3	(4)	4	na	3	4	na	
Median		(0)%	91 %			22.0 x	20.7 x	16.8 x	11.1 x	10.3 x	8.2 x	1.7 x	1.5 x	1.4 x	5 %	7 %	14 %	17 %	18 %	1.4 x	
Mean		1	84			21.1	22.8	18.9	15.8	10.2	8.8	1.8	1.6	1.5	9	8	14	16	16	1.6	
Healthcare Services																					
Microsoft	44.39	(0)	89	359,096	295,698	20.9	17.6	16.3	8.8	8.7	7.8	3.1	3.2	3.0	(1)	5	9	37	39	1.9	
Oracle	40.15	(0)	86	178,847	166,872	21.8	15.2	14.1	10.4	9.5	9.1	4.4	4.4	4.2	(1)	3	7	46	47	2.1	
IBM	164.73	0	84	162,334	192,500	12.7	10.4	10.1	8.2	8.3	8.2	2.1	2.3	2.3	(11)	(0)	8	28	28	1.2	
VMware	83.06	(2)	80	35,665	29,943	46.6	20.8	18.3	19.3	13.2	11.7	4.8	4.5	4.0	10	11	18	34	35	1.2	
Merge	4.62	1	75	452	707	nm	20.7	16.7	19.5	13.6	11.5	3.3	2.8	2.6	16	9	16	21	23	1.3	
Median		(0)%	84 %			15.9 x	17.6 x	16.3 x	7.8 x	9.5 x	9.1 x	0.9 x	3.2 x	3.0 x	(1)%	5 %	9 %	34 %	35 %	1.3 x	
Mean		(1)	85			15.9	16.0	14.7	7.7	9.9	9.2	1.2	3.6	3.4	(1)	5	11	36	37	1.6	
Evolent Health	19.94	2	97	792	784	nm	nm	nm	nm	nm	nm	6.7	5.0	3.7	56	35	30	nm	nm	na	







¥ i

Overview of FT Partners

FT Partners is the Leader in Financial Technology Investment Banking

FT Partners has advised on the most prominent transactions in the Healthcare IT Space




- Offers end-to-end Revenue Cycle Management, Quality and Care Coordination and Physician Advisory Services
- Differentiated solutions span the entire healthcare revenue cycle
- Infused management model integrates people, processes and technology



- Performs
 outsourced
 healthcare Payment
 Integrity and
 Recovery Services
- Medicare Recovery Audit Contractor ("RAC") for Region A (Northeast)
- Recovered ~\$482 mm in improper
 Medicare payments in 2012



- Second largest wholesale broker in the U.S. by premiums placed (1)
- Group Benefits division develops, distributes and administers benefits products through 7 individual operating companies
- Division services approximately 843,000 member lives among 10,000 employer groups



- Provides technology-enabled content and communication, agency automation and business intelligence tools
- Serves the employee benefits and P&C insurance distribution industry
- Software and products are used by more than 2,600 agencies





Overview of FT Partners

2014

2012

2011

2010

2007

Award-Winning Investment Banking Franchise Focused on Financial Technology

■ Equity Financing Deal of the Year

FT Partners has been recognized as Investment Banking Firm of the Year and regularly achieves Merger and Financing Deal of the Year recognition



M&A Advisor Awards ■ Professional Services Deal of the Year, Above \$100mm

Dealmaker of the Year

■ Deal of the Decade

■ Professional Services Deal of the Year, Above \$100 mm

■ Boutique Investment Bank of the Year

■ 10 Deal of the Year Nominations Across 9 Categories

■ Upper Middle Market Deal of the Year, Above \$500 mm

■ IT Services Deal of the Year, Below \$500mm

■ Cross-Border Deal of the Year, Below \$500mm

■ Dealmaker of the Year – Steve McLaughlin

Business to Business Services Deal of the Year

■ Computer and Information Technology Deal of the Year, Above \$100mm

■ Financial Services Deal of the Year, Above \$100mm

Institutional Investor Institutional Investor Annual Ranking

2006-2008

■ Steve McLaughlin consecutively ranked (2006, 2007 and 2008) among the top Bankers in Financial Technology



Financing Awards

2008

2006

- Equity Financing Dealmaker of the Year Steve McLaughlin
- Information Technology Deal of the Year
- Financial Services Deal of the Year

■ Financing Professional of the Year – Steve McLaughlin

- Financing Deal of the Year Equity
- Financing Deal of the Year Debt

